Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
about
Pancreatic Cancer from Molecular Pathways to Treatment OpinionPancreatic cancer from bench to bedside: molecular pathways and treatment optionsState of the art biological therapies in pancreatic cancerK-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.Pancreatic cancer: pathobiology, treatment options, and drug delivery.Pancreatic cancer: molecular pathogenesis and new therapeutic targets.Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.The molecular targets for the diagnosis and treatment of pancreatic cancer.Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.Emerging drugs in the treatment of pancreatic cancer.Targeted therapy in gastrointestinal malignancies.Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Emerging cell-cycle inhibitors for pancreatic cancer therapy.Promising new therapies in advanced pancreatic adenocarcinomas.Emerging protein kinase inhibitors for treating pancreatic cancer.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Effect of arenobufagin on human pancreatic carcinoma cells.
P2860
Q26743482-CA9DF187-F4D8-48BD-AFE2-7183C4C01128Q26747524-D4351F3F-C8B2-45BA-AACE-B19D90E787CDQ26769941-33602C8A-94CC-4C18-9576-64AA92013EA2Q30250097-FC41CB79-3BF9-4C14-86BE-118D952C73F9Q33570512-AF0AE481-CEDF-4898-949B-E9B44967BC1AQ33749460-DCB47CCF-4DCC-4655-A4FE-0EBD21D1DBB3Q33899954-298CF06A-6DF7-42A5-B6F7-CB36A5A574E4Q33943421-1E0E0E7C-1111-4DD7-8BB4-F4B178E5C1D8Q34494019-E6AB63F7-1EF9-4241-832F-0ABA7A756FDDQ34497010-6CF01765-1A4D-4471-86DC-3D599FCE9EA5Q36402262-48A5D699-A711-48E1-AC45-8551ED222F53Q37354440-09265864-2C62-4D22-9C81-A0E005EDDD9DQ37494647-1FAFC408-6F8E-418F-8FF3-11250D0F0486Q37702506-204D1AA5-BEFA-44CE-8DBE-C80964797F32Q37877173-A275CD48-899D-4345-AB7F-ECF64E8C5D06Q38053855-6B04AFEF-F4AF-40B5-8703-571C136CB15BQ38057759-50E65AA1-B18F-436B-A603-E3ED8EDD63A3Q38296663-18E86687-E0B6-431E-8B25-6F8726F72EBCQ39158411-EFDF8AF0-A7DB-471E-848D-E49A1999D71AQ39390859-41F60F57-BA75-4D3E-807E-987CF8F5BC73Q47170368-97E590A6-A7AA-43E3-997D-0941FCB37A30
P2860
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Gemcitabine combined with gefi ...... oup with biomarker evaluation.
@en
Gemcitabine combined with gefi ...... oup with biomarker evaluation.
@nl
type
label
Gemcitabine combined with gefi ...... oup with biomarker evaluation.
@en
Gemcitabine combined with gefi ...... oup with biomarker evaluation.
@nl
prefLabel
Gemcitabine combined with gefi ...... oup with biomarker evaluation.
@en
Gemcitabine combined with gefi ...... oup with biomarker evaluation.
@nl
P2093
P2860
P1433
P1476
Gemcitabine combined with gefi ...... oup with biomarker evaluation.
@en
P2093
Angelos K Koutras
Anna Kalogera-Fountzila
Christos Christodoulou
Dimitrios Bafaloukos
Epaminondas Samantas
Georgia Karayannopoulou
Helena Linardou
Konstantine T Kalogeras
Nikolaos Xiros
Paris Kosmidis
P2860
P304
P356
10.1080/07357900801918611
P577
2008-10-01T00:00:00Z